Начало・Списък с акции・Gossamer Bio Inc

Gossamer Bio Inc

Отворен

СекторЗдравеопазване

0.18 5.88

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.16

Максимум

0.18

Ключови измерители
By Trading Economics
Приходи	574K -47M
Продажби	3.2M 17M
EPS	-0.2
Марж на печалбата	-275.223
Служители	161
EBITDA	2.1M -44M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+529.41% upside

Дивиденти
By Acuity
Следващи печалби	10.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	18M 97M
Предишно отваряне	-5.7
Предишно затваряне	0.18

Настроения в новините

By Acuity

63%

37%

285 / 340 Класиране в Healthcare

Gossamer Bio Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 23:06 ч. UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

1.08.2026 г., 00:02 ч. UTC

Social Media

Gossamer Bio Inc shares are lower in after-market hours, continuing a downward trend following recent gains tied to an FDA update on Seralutinib.

31.07.2026 г., 23:41 ч. UTC

Social Media

Gossamer Bio Inc. shares are higher in after-market trading following an FDA update on Seralutinib, its candidate for pulmonary arterial hypertension.

30.07.2026 г., 23:02 ч. UTC

Gossamer Bio Inc is higher in after-market hours, reflecting broader market gains. The stock benefits from positive sentiment in the biotech sector.

29.07.2026 г., 22:31 ч. UTC

Gossamer Bio Inc. shares declined in after-market hours, reflecting unusual movement despite being above its 20-day moving average and near a one-month range high.

28.07.2026 г., 23:41 ч. UTC

Gossamer Bio Inc. shares are lower in after-market hours amid broader market declines, particularly in Asia's technology sector due to AI spending concerns.

27.07.2026 г., 23:51 ч. UTC

Social Media

Gossamer Bio Inc shares are higher in after-market trading following an upgrade to Outperform from Leerink and an FDA regulatory update on Seralutinib.

24.07.2026 г., 22:01 ч. UTC

Gossamer Bio Inc shares rose during after-market trading, reflecting notable strength despite mixed global equity market performance and without any specific company news identified.

23.07.2026 г., 23:01 ч. UTC

Gossamer Bio Inc's shares are higher in after-market trading, recovering from earlier losses despite no specific news to explain the movement.

22.07.2026 г., 23:01 ч. UTC

Gossamer Bio Inc shares are higher in after-market trading, reflecting a notable rise since Wednesday's close amid rising crude oil prices and geopolitical tensions.

21.07.2026 г., 21:01 ч. UTC

Gossamer Bio Inc shares are higher in after-market hours, buoyed by positive sentiment from better-than-expected second-quarter results across major companies.

20.07.2026 г., 23:01 ч. UTC

Gossamer Bio Inc shares are trading higher in after-market hours, despite no specific news, amid broader market volatility and inflation concerns.

Сравнение с други в отрасъла

Ценова промяна

Gossamer Bio Inc Прогноза

Ценова цел

By TipRanks

529.41% нагоре

12-месечна прогноза

Среден 1.07 USD 529.41%

Висок 2 USD

Нисък 0.28 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Gossamer Bio Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Gossamer Bio Inc през последните 3 месеца.

Настроение

By Acuity

285 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.